The original benefactors to the University of Florida's Powell Gene Therapy Center have donated another $5 million.

The contribution by Earl and Christy Powell of Miami will establish a chair in gene therapy and genetics research at the UF Health Science Center, UF announced Wednesday. The Powells first donated $2 million in 2000 to UF's program in gene therapy research and the university renamed the center in their name.

The center has worked on gene therapies aimed at helping patients with inherited blindness and paralyzing neuromuscular diseases. The new chair will focus on the developing methods for the delivery of therapeutic genes to patients with a variety of diseases, according to UF.

Earl Powell is a former UF trustee and founding partner of Trivest Partners, a private equity investment firm in Miami.

– Nathan Crabbe

Powells donate $5 million to Gene Therapy Center Gainesville.comFebruary 22, 2012 1:03 PM

<p>The original benefactors to the University of Florida's Powell Gene Therapy Center have donated another $5 million.</p><p>The contribution by Earl and Christy Powell of Miami will establish a chair in gene therapy and genetics research at the UF Health Science Center, UF announced Wednesday. The Powells first donated $2 million in 2000 to UF's program in gene therapy research and the university renamed the center in their name. </p><p>The center has worked on gene therapies aimed at helping patients with inherited blindness and paralyzing neuromuscular diseases. The new chair will focus on the developing methods for the delivery of therapeutic genes to patients with a variety of diseases, according to UF. </p><p>Earl Powell is a former UF trustee and founding partner of Trivest Partners, a private equity investment firm in Miami.</p><p><i>- Nathan Crabbe</i></p>

Copyright 2012 Gainesville.com – All rights reserved. Restricted use only.

Read the original post:
Powells donate $5 million to Gene Therapy Center

ATLANTA, GA–(Marketwire -02/21/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB – News) (OTCQB: VSTA.OB – News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has retained MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Through a network of investor-oriented online websites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital and improve shareholder value.

“VistaGen's work with human stem cell technology is groundbreaking,” said Sherri Snyder, Director of Marketing at MissionIR. “The company's versatile platform, Human Clinical Trials in a Test Tube™, provides clinically relevant predictions of potential heart toxicity of new drug candidates long before they are ever tested on humans. Guided by a management team with decades of experience, VistaGen's stem cell technology can potentially save billions of dollars in the healthcare industry while recapturing prior R&D investment in once-promising new drug candidates.”

“We are pleased to bring MissionIR on board as our external investor relations partner,” said Shawn Singh, VistaGen's Chief Executive Officer. “The crucial work our company is doing can fundamentally change the way medicine is developed. Paired with MissionIR's global presence and sound investor relations programs, we can further grow our shareholder base and accelerate internal initiatives already in place to bring our stem cell technology platform to the forefront of drug development.”

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. Through a full suite of investor relations and consultancy services, we help public companies develop and execute a strategic investor awareness plan as we've done for hundreds of others. Whether it's capital raising, increasing awareness among the financial community, or enhancing corporate communications, we offer a variety of solutions to meet the objectives of our clients.

For more information, visit www.MissionIR.com

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants of once-promising small-molecule drug candidates. These are once-promising drug candidates discontinued by pharmaceutical companies during development due to heart toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans.

Additionally, VistaGen's small molecule drug candidate, AV-101, is in Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen plans to initiate Phase 2 clinical development of AV-101 in the fourth quarter of 2012. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson's disease and depression. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.

Original post:
VistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor

CAMBRIDGE, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) — Pathfinder Cell Therapy, Inc. (“Pathfinder,” or “the Company”) (OTCQB:PFND.PK – News), a biotechnology company focused on the treatment of diabetes and other diseases characterized by organ-specific cell damage, today presented preliminary data highlighting the potential of the Company's unique cell-based therapy for treating diabetes at the 7th Annual New York Stem Cell Summit. Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, provided an overview of the Company's Pathfinder Cell (“PC”) technology, and presented preclinical evidence demonstrating how treatment with PCs was able to reverse the symptoms of diabetes in two different mouse models.

Pathfinder Cells are a newly identified non-stem cell mammalian cell type that has the ability to stimulate regeneration of damaged tissue without being incorporated into the new tissue. In today's presentation, Dr. Franklin showed how recent experiments performed using a non-obese diabetic (NOD) mouse strain were supportive of earlier data that demonstrated complete reversal of diabetes in mice. The earlier results, which used a drug-induced diabetic mouse model, were published in Rejuvenation Research1. Though preliminary, the recent results are encouraging because the NOD mouse model is widely used and highly regarded as being predictive of human type-1 diabetes.

In three separate experiments using this model, 30-50% of the mice treated with PCs at the onset of diabetes returned to normal blood glucose levels. Of the mice that responded well to treatment, the effects tended to be long lasting, up to two months in some cases after just two doses. These results, which were generated by intravenous injection of PC's derived from rat pancreatic tissue, further demonstrate the remarkable ability of Pathfinder Cells to elicit their positive effect regardless of the organ, or even species, of origin.

“We are very encouraged by these preclinical results using NOD mice. This model is the gold standard for type-1 diabetes and the fact that recent experiments mirror what we've seen in previous models may be highly significant,” stated Dr. Franklin. “We have many questions to answer about how PCs act in the body, but we believe, based on previous experiments, that PCs may stimulate regeneration of damaged islet cells that produce insulin. The current NOD mouse data also suggest that PCs may have an effect in modulating the auto-immune process in type 1 diabetes. We continue to conduct experiments aimed at elucidating the optimal dosing and other factors that may be responsible for producing a robust and long-lasting response, as this will be critical as we start to think about how PCs may be used in treating human diabetes.”

In his presentation today, Dr. Franklin also provided further insight into the mechanism of action of PCs, based on recent animal experiments. It was observed previously that PCs produce microvesicles, which are known to play a role in intercellular communication, but through mechanisms that are poorly understood. In a recent experiment, Pathfinder was able to isolate these microvesicles from the PCs and treat animals directly with an injection containing microvesicles only. Remarkably, both PC- and microvesicle-treated mice exhibited similar reductions in blood glucose compared to controls using the same drug-induced diabetes mouse model. This suggests, not only that the microvesicles produced by PCs are central to the mechanism of action, but that the microvesicles alone appear to be sufficient to produce the full effect.

Dr. Franklin commented, “If confirmed, this finding could have a significant positive impact on the future of PC-based therapy. Due to the relatively small amount of material contained within the microvesicles, determining the specific factor(s) that are responsible for regenerating damaged tissue could be more straightforward than we first anticipated, bringing us closer to understanding the mechanism of action. There may also be a number of potential manufacturing and storage benefits to using microvesicles versus PCs that will be interesting to explore in parallel as we work to advance this innovative new therapeutic approach closer to human clinical development.”

The New York Stem Cell Summit brings together cell therapy company executives, researchers, investors and physicians to explore investment opportunities in cell therapy research and innovation. More information can be found at www.stemcellsummit.com.

Presentation details Event: 7th Annual New York Stem Cell Summit Date: Tuesday, February 21, 2012 Place: Bridgewaters New York, 11 Fulton Street, New York, NY Time: 3:35 pm ET

About Pathfinder

Pathfinder is developing a novel cell-based therapy and has generated encouraging preclinical data in models of diabetes, renal disease, myocardial infarction, and critical limb ischemia, a severe form of peripheral vascular disease. Leveraging its internal discovery of Pathfinder Cells (“PCs”) Pathfinder is pioneering a new field in regenerative medicine.

PCs are a newly identified mammalian cell type present in very low quantities in a variety of organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood. Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the newly generated tissue. Based on testing to date, the cells appear to be “immune privileged,” and their effects appear to be independent of the tissue source of PCs. For more information please visit: www.pathfindercelltherapy.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to obtain additional required financing; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results, if any; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; technological changes; and government regulation. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

1Karen Stevenson, Daxin Chen, Alan MacIntyre, Liane M McGlynn, Paul Montague, Rawiya Charif, Murali Subramaniam, W.D. George, Anthony P. Payne, R. Wayne Davies, Anthony Dorling, and Paul G. Shiels. Rejuvenation Research. April 2011, 14(2): 163-171. doi:10.1089/rej.2010.1099

Here is the original post:
Pathfinder Presents Preliminary Data on New Regenerative Approach to Diabetes Treatment

www.youtube.com/watch?v=Jf6_vhw540U

Here is the original post:
Reverse Aging Discovery thru Stem Cell Research – Video

www.youtube.com/watch?v=SkVxgsUzk64

Originally posted here:
W1LSON – Chronic Hourz (Episode 1) @OFFICIALW1LSON – Video

Dulbecco developed a method for measuring the quantity of virus in animal cells in tissue culture, a finding that greatly facilitated the study of such viruses and paved the way for the development of the Sabin polio vaccine. He was a faculty member at Caltech from 1949 to 1963 before moving to the Salk Institute for Biological Studies in La Jolla. He later served as president of the institute.

FOR THE RECORD:
Renato Dulbecco: A news obituary in the Feb. 21 LATExtra section of Nobel Prize-winning virologist Renato Dulbecco misspelled the first name of Italian anatomist Giuseppe Levi as Giuseppi. —

Dulbecco was also one of the first proponents of the human genome project, which many researchers initially thought would be both excessively expensive and relatively useless but which has since proved invaluable in biological research.

“Renato was one of the most brilliant scientific minds of our generation,” current Salk Institute President William R. Brody said in a statement. “His contributions have truly made this a better world for all of us.”

It has been known since the early 1900s that certain viruses can cause tumors in animals. The best-known example was the Rous sarcoma virus, which causes cancer in chickens. But it was not clear how the viruses produced this effect and what proportion of human cancers might be attributed to them.

In experiments carried out at Caltech in the 1950s, Dulbecco showed that a viral infection can have two outcomes: the virus can multiply inside the cell, killing the cell and releasing thousands of new viruses into the host animal; or it could alter the cell so that the cell would continue to divide and grow indefinitely, a process called transformation.

In the latter case, no new virus particles appear and the infecting virus seemingly disappears.

Through an elegant series of experiments, Dulbecco showed that the DNA from the polyoma virus became integrated into the DNA of the host cell, where it was replicated intact every time the cell replicated. Moreover, the viral DNA served as the blueprint for a small number of proteins that subverted cellular machinery, causing the cells to reproduce repeatedly — the hallmark of tumor formation.

Additionally, this feat was achieved before it was possible to sequence the DNA of either viruses or animal cells.

For his achievement, Dulbecco shared the 1975 Nobel Prize with Howard Temin and David Baltimore, who demonstrated the existence of an enzyme — reverse transcriptase — that allowed RNA viruses to integrate their genes into a host cell in the same fashion as the DNA viruses studied by Dulbecco. Both were former students of his.

In his Nobel address, Dulbecco called for increased restrictions on tobacco use because of its carcinogenic potential and urged governments to make greater efforts to limit the introduction of dangerous chemicals.

“While we spend our life asking questions about the nature of cancer and ways to prevent or cure it,” he said, “society merrily produces oncogenic substances and permeates the environment with them.”

Renato Dulbecco was born Feb. 22, 1914, in Catanzaro, Italy, the son of a civil engineer. He enrolled at the University of Turin, where he had meant to study physics and chemistry but soon became interested in biology instead.

He received his medical degree in 1936 and during World War II served in France and Russia, where he was injured in 1942 during a major Russian offensive along the Don River.

After several months of hospitalization, he returned home, hiding out in a small village near Turin when German forces occupied Italy after Mussolini's fall. He served as a medical officer for partisan forces resisting the occupation.

In medical school, Dulbecco had worked in the laboratory of noted anatomist Giuseppi Levi, along with fellow students Salvador Luria and Rita Levi-Montalcini, both of whom also became Nobel laureates. In 1946, Luria invited Dulbecco to join his small laboratory at the Indiana University and Dulbecco immigrated the following year, becoming a U.S. citizen in 1953. At IU, he shared bench space with James Watson, another eventual Nobel laureate.

Dulbecco was working with bacteriophage, small viruses that invade only bacteria cells. He showed that bacteriophage that had been disabled by exposure to ultraviolet light could be reactivated by exposing them to bursts of white light.

That work attracted the attention of microbiologist Max Delbruck, who invited Dulbecco to join him at Caltech. In the summer of 1949, Dulbecco and his then-wife, the former Giuseppina Salvo, drove an old car cross-country. He wrote in his Nobel autobiography that he was struck by “the beauty and immensity of the U.S.A. and the kindness of its people” and vowed to continue to live here forever.

While at Caltech, Dulbecco adapted a technique he had used with bacteriophage to count the number of virus particles that are present in a tissue sample. Dubbed the plaque assay technique, the assay relies on the fact that viruses added to a culture of cells kill small areas of cells, producing clear circles that can be counted.

This technique enabled researchers for the first time to measure the concentrations of virus in a sample and was crucial to Albert Sabin's work in inventing an attenuated virus polio vaccine. Dulbecco, in fact, originally isolated the mutant polio virus used by Sabin in his vaccine.

In 1962, Dulbecco became a founding member of the Salk Institute, where he remained for the rest of his career. He also spent time at the Imperial Cancer Fund Research Laboratories in London, where he worked on human cancer viruses, although he remained on the staff at Salk. In his later years, he researched breast cancer and concluded that breast cancer stem cells gone awry might be responsible for certain types of breast tumors.

In 1988, he became interim president at Salk, a position that soon became permanent. He held the post until he returned to his laboratory research in 1992.

During the 1980s, Dulbecco had argued passionately in favor of a human genome project. After his retirement as Salk president he was asked by the Italian National Research Council to develop an Italian human genome project, and he spent about half his time each year in that country. The project was abandoned after five years, however, because of lack of funding and facilities.

Dulbecco was a classically trained pianist who was passionate about music and performed opera. He was also a dedicated do-it-yourself handyman and once told The Times, “If I can get a week off to work on the house, that's the best vacation I can get.” He remodeled his kitchen and added about 1,000 square feet of space to his home in La Jolla, performing all the work — including plumbing and electrical — himself.

Dulbecco is survived by his second wife, Maureen, whom he married in 1962; a brother, two daughters and four grandchildren. A son predeceased him.

Maugh is a former Los Angeles Times staff writer.

news.obits@latimes.com

Excerpt from:
Renato Dulbecco dies at 97; 1975 Nobel Prize winner in medicine

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/b93d9c/evolutionary_biolo) has announced the addition of John Wiley and Sons Ltd's new book “Evolutionary Biology: Cell-Cell Communication, and Complex Disease” to their offering.

Evolutionary Biology: Cell-Cell Communication, and Complex Disease – An Integrative View of the Evolution of Genetics and the Natural World

Even in this advanced age of genomics, the evolutionary process of unicellular and multicellular organisms is continually in debate. Evolutionary Biology, Cell-Cell Communication, and Complex Disease challenges current wisdom by using physiology to present an integrative view of the nature, origins, and evolution of fundamental biological systems.

Providing a deeper understanding of the way genes relate to the traits of living organisms, this book offers useful information applying evolutionary biology, functional genomics, and cell communication studies to complex disease. Examining the 4.5 billion-year evolution process from environment adaptations to cell-cell communication to communication of genetic information for reproduction, Evolutionary Biology hones in on the “why and how” of evolution by uniquely focusing on the cell as the smallest unit of biologic structure and function.

Based on empirically derived data rather than association studies, Evolutionary Biology covers:

A model for forming testable hypotheses in complex disease studies The integrating role played by the evolution of metabolism, especially lipid metabolism The evolutionary continuum from development to homeostasis Regeneration and aging mediated by signaling molecules

Key Topics Covered:

1 THE CELLULAR ORIGIN OF VERTEBRATES

2 REDUCING LUNG PHYSIOLOGY TO ITS MOLECULAR PHENOTYPES

3 A CELL-MOLECULAR STRATEGY FOR SOLVING THE EVOLUTIONARY PUZZLE

4 THE EVOLUTION OF CELL-CELL COMMUNICATION

5 HOW TO INTEGRATE CELL-MOLECULAR DEVELOPMENT, HOMEOSTASIS, ECOLOGY, AND EVOLUTIONARY BIOLOGY: THE MISSING LINKS

6 FROM CELL-CELL COMMUNICATION TO THE EVOLUTION OF INTEGRATED PHYSIOLOGY

7 EXPLOITING CELL-CELL COMMUNICATION ACROSS SPACETIME TO DECONSTRUCT EVOLUTION

8 THE PERIODIC TABLE OF BIOLOGY

9 VALUE ADDED BY THINKING IN TERMS OF THE CELL-CELL COMMUNICATION MODEL FOR EVOLUTION

10 CELL-CELL COMMUNICATION AS THE BASIS FOR PRACTICING CLINICAL MEDICINE

Author:

John Torday, PhD, is Professor of Pediatrics and Ob/Gyn at Harbor-UCLA Medical Center where he is also Director of The Henry L. Guenther Laboratory for Cell/Molecular Research and Director of Laboratory for Evolutionary Preventive Medicine.

V.K. Rehan, MD, is Professor of Pediatrics and Director of the Neonatal Intensive Care Unit at Harbor-UCLA Medical Center. The recipient of numerous teaching honors, Dr. Rehan is involved both in treating patients and continuing research on neo and peri-natal respiratory issues and lung development.

For more information visit http://www.researchandmarkets.com/research/b93d9c/evolutionary_biolo

See the original post:
Research and Markets: Evolutionary Biology: Cell-Cell Communication, and Complex Disease – An Integrative View of the …

SAN DIEGO–(BUSINESS WIRE)–

Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that two of its senior scientists, Farideh Bischoff, Ph.D., Vice President of Translational Research, and Lyle Arnold, Ph.D., Senior Vice President, R&D and Chief Scientific Officer, will be making presentations at the 19th Annual Molecular Medicine Tri-Con being held in San Francisco February 19-23.

Dr. Arnold spoke during the “Blood-Based Cancer Diagnostics” session on Monday, February 20th. His talk, entitled “The Capture, Identification and Interrogation of Circulating Tumor Cells,” touched on a proprietary, highly sensitive mutation detection technology developed at Biocept called “SelectorTM.” Dr. Bischoff will speak during the “Clinical Use of Circulating Tumor Cells” session on Wednesday, February 22nd. Her talk, entitled “Capture and Detection of CK+ and CK- CTCs for Subsequent Molecular Analysis Using the OncoCEETM Platform,” will cover in part a continuing clinical study in breast cancer with collaborators at the MD Anderson Cancer Center.

Biocept’s first test, OncoCEE-BRTM for breast cancer, is available through its commercialization partner Clarient, Inc., a GE Healthcare Company. The test includes CTC enumeration and determination of HER2 status by fluorescence in situ hybridization (FISH) from a blood sample. Determination of estrogen receptor (ER) and progesterone receptor (PR) status by immunocytochemical staining will be added to the test later this year. OncoCEE-BR is the first commercially available CTC test to include analysis of a specific, treatment-associated biomarker (HER2).

About Biocept, Inc.

Biocept, Inc., headquartered in San Diego, California, is an advanced laboratory services company specializing in the capture, isolation, detection and analysis of Circulating Tumor Cells (CTCs). Biocept’s mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes patented and innovative technologies to deliver clinically relevant and actionable information to physicians that enable better patient care. This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with important information for the treatment of their patients with cancer.

Original post:
Biocept to Present at the Molecular Medicine Tri-Conference on Circulating Tumor Cell (CTC) Technologies

Global leader in animal stem cell technology is poised for significant expansion through new partnership with top U.S. companion animal health distribution company.

Las Vegas, Nevada (PRWEB) February 22, 2012

MediVet-America, the global leader in veterinary stem cell technology and regenerative medicine, has entered into a distribution partnership with Butler Schein Animal Health, a division of Henry Schein, the leading companion animal health distribution company in the U.S., to sell and distribute stem cell kits and equipment to veterinarians serving the nation’s fast-growing $50 billion pet industry.

The announcement was made today at the Western Veterinary Conference in Las Vegas by Jeremy Delk, CEO of MediVet-America.

The two companies will partner to sell and distribute MediVet-America’s advanced stem cell technology to more than 26,000 veterinary clinics nationwide. Adult animal stem cell technology uses the body’s own regenerative healing power to help treat dogs, cats, horses and other animals suffering from painful arthritis, hip dysplasia and tendon, ligament and cartilage injuries and other ailments.

The Adipose-Derived Stem Cell Procedure Kit and state of the art equipment, co-developed with Medical Australia, enable veterinarians to remove a small sample of fat, separate the stem cells, then activate and inject them into affected areas.

“We are pleased to be teaming up with Butler Schein, the largest companion animal health distribution company in the nation,” said Delk. “Their strong track record in sales and distribution will further fuel our rapid growth and bring this breakthrough technology to more leading veterinary practices across the country.”

To introduce the distribution partnership, Delk said MediVet-America has developed an exclusive program of product and service offers that will be made available only to Butler Schein customers.

Veterinary practitioners in more than 200 markets throughout 42 states now perform the drug-free procedure entirely in their own clinics more quickly, effectively and economically than earlier generation animal stem cell therapy. MediVet-America’s new treatment, developed in Australia, is available in 26 countries worldwide.

“This exciting partnership will allow even more of our colleagues unparalleled access to MediVet-America’s superior technology, providing the most affordable and efficacious stem cell therapy in the industry,” said Mike Hutchinson, D.V.M., the world’s leading animal stem cell practitioner. Dr. Hutchinson, who has spoken around the world about stem cell therapy, most recently in Tokyo, has performed more than 300 procedures over the last 18 months in his practice near Pittsburgh, PA.

Partnering with the leading animal health manufacturers in the world, Butler Schein maintains an order-fill ratio greater than 98 percent, and is positioned to bring the broadest selection of veterinary products and strategic business solutions to veterinarians, including:

    A comprehensive product offering for companion animal, equine and large animal practices including biologicals, diagnostics, nutritionals, parasiticides and pharmaceuticals

    Technology hardware and software solutions     Capital equipment, supply products and repair services     Practice design and remodeling, client marketing and financial solutions

Stem cells are basic biological cells with the ability to differentiate into specialized tissue cells and regenerate new cells to replace or repair damaged tissue. The stem cells used in veterinary medicine are not embryonic, which have attracted controversy over the years, but are taken from adipose (fat) tissue of the adult animal.

Americans spent an estimated $50.8 billion in 2011 on their companion animals, according to the American Pet Products Association, up from $28.5 billion in 2001. MediVet-America’s stem cell treatment costs about $1,800 for small animals, $2,400 for horses. Stem cells also can be frozen and banked for future use through MediVet Lab Services.

MEDIVET-AMERICA

A research and development company and global leader in veterinary stem cell technology, MediVet-America provides innovative cell applications for the therapeutic care of animals. Headquartered in Nicholasville, Kentucky, MediVet-America develops advanced cellular designed kits and services for the treatment of arthritis and degenerative joint disease. The company also offers MediVet Lab Services in multiple locations around the world that provides technical support for in-house stem cell vets, as well as regional and national Adipose stem cell processing and cryo banking services for pets at a young age or for a maintenance program, autologous conditioned serum processing, and cell counting for in-house stem cell procedures. http://www.MediVet-America.com

BUTLER SCHEIN ANIMAL HEALTH

Butler Schein Animal Health is the leading U.S. companion animal health distribution company. Headquartered in Dublin, Ohio, the company operates through 18 distribution centers and 12 telecenters. Approximately 900 Butler Schein Animal Health team members, including 300 field sales representatives and 200 telesales and customer support representatives, serve animal health customers in all 50 states. http://www.ButlerShein.com

###

Dick Roberts
Roberts Communications
(412) 535-5000
Email Information

More:
MediVet-America Partners With Butler Schein Animal Health to Distribute World's Leading Animal Stem Cell Technology to …

AUSTIN, Texas, Feb. 21, 2012 /PRNewswire/ – Celling Biosciences announces a sponsorship of the 7th Annual Stem Cell Summit being held on February 21st at Bridgewaters New York in New York City. The Stem Cell Summit is consistently the premiere venue for the world's leaders in regenerative medicine to network and promote next generation technologies and cell therapies.

The meeting will feature more than 30 thought leaders in stem cell therapy including Dr. Kenneth Pettine of the Orthopedic Stem Cell Institute in Loveland, Colorado.  Dr. Pettine has teamed up with Celling Biosciences' SpineSmith Division to present “Adult Stem Cell Therapy for Orthopedic and Spine Conditions Resulting from Injury or Aging.”  Dr. Pettine has become an innovator in the regenerative cell therapy market and believes “regenerative therapies will become the next standard of care in treating many orthopedic conditions.” 

Following the Stem Cell Summit, Dr. Pettine will be presenting a discussion on regenerative therapies to the trainers and medical staff attending this year's NFL combine.  The NFL has recently gained attention from Peyton Manning going oversees to receive a cell therapy treatment for his cervical spine condition.  Dr. Pettine envisions a day when these professional athletes stop going to foreign countries to receive medical treatment.

The Orthopedic Stem Cell Institute provides state-of-the-art regenerative cell therapy using Celling Biosciences' ART 21 system. The ART 21 system processes bone marrow from the patient at the point of care to consistently produce a concentrate of regenerative cells with high yields of mononuclear stem cells in less than 15 minutes.  Celling Biosciences provides the cell separation systems along with the biomaterials and devices necessary to recreate the environment to promote healing. 

Kevin Dunworth, founder of Celling Biosciences, believes regenerative cell therapy has more to do with creating the optimal environment then just providing cells.  “We believe autologous cell therapy is a viable solution but physicians need to understand that these cells require the necessary substrate for delivery and the proper techniques for retrieval.  Our focus has been on providing not only cell separation technologies, medical devices and biomaterials but also the registered nurses to deliver the service so physicians can have the most consistent, reliable and predictable regenerative cell therapy for their patients.”

Contact:
Tracy Gladden
Communications Manager
Tgladden@spinesmithusa.com
512-637-2050

About Celling Biosciences
Celling Biosciences, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the field of regenerative medicine. www.cellingbiosciences.com and www.spinesmithusa.com

Visit link:
Celling Biosciences Sponsors 7th Annual Stem Cell Summit